HK
Elite in Pancreatic Cancer

Dr. Hedy L. Kindler

Duchossois Center For Advanced Medicine (DCAM) - Hyde Park
Chicago, IL
Elite
 in Pancreatic Cancer
Specialties:Hematology Oncology | Hematology | Oncology
Experience:34 Years
Clinical Trials:Currently Recruiting for 11 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Hedy L. Kindler's experience treating your condition:
About Dr. Hedy L. Kindler

Hedy Kindler is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Kindler has been practicing medicine for over 34 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 18 other conditions, according to our data. Her top areas of expertise are Malignant Mesothelioma, Pancreatic Cancer, Metastatic Pleural Tumor, Pancreatic Adenoma, and Orchiectomy. She is licensed to treat patients in Illinois. Kindler is currently accepting new patients.

Her clinical research consists of co-authoring 183 peer reviewed articles and participating in 46 clinical trials in the past 15 years. In particular, she has co-authored 52 articles and participated in 16 clinical trials in the study of Pancreatic Cancer.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Hedy L. Kindler it is best to call her office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
5758 S Maryland Ave, Chicago, IL 60637
Other Locations
5841 S Maryland Ave, Mc 2115, Chicago, IL 60637
Background & Education
Graduate Institution
State University Of New York At Buffalo School Of Medicine, 1989
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
UChicago Medicine Ingalls Memorial Hospital
UChicago Medicine Mitchell Hospital
Northwest Community Hospital
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

42 Clinical Trials
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Drug
Study Drugs: TSR-022NivolumabTSR-042TSR-033Docetaxel
Study Phase: Phase 1
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Enrollment Status: Recruiting
Publish Date: December 01, 2022
Intervention Type: Drug
Study Drugs: INBRX-109 Tetravalent DR5 Agonist AntibodyCarboplatinCisplatinPemetrexed5-FluorouracilIrinotecan
Study Phase: Phase 1
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
Enrollment Status: Recruiting
Publish Date: November 25, 2022
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: CarboplatinCisplatinPemetrexedPemetrexed Disodium
Study Phase: Phase 3
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: November 01, 2022
Intervention Type: Drug
Study Drug: SGN-CD228A
Study Phase: Phase 1
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Recruiting
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Enrollment Status: Recruiting
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: CPI-0209Irinotecan
Study Phase: Phase 1/Phase 2
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Enrollment Status: Recruiting
Publish Date: August 25, 2022
Intervention Type: Drug, Procedure, Biological
Study Drugs: AtezolizumabBevacizumabCarboplatinHyperthermic Intraperitoneal ChemotherapyPemetrexed
Study Phase: Phase 2
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drugs: GemcitabineNab-paclitaxelSM-88mFOLFIRINOX
Study Phase: Phase 3
A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Enrollment Status: Recruiting
Publish Date: June 30, 2021
Intervention Type: Drug
Study Drugs: PembrolizumabCisplatin and Pemetrexed
Study Phase: Phase 1
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
Enrollment Status: Recruiting
Publish Date: May 14, 2021
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
A Phase 2 Study of BAY 43-9006 for Imatinib- and Sunitinib Resistant Gastrointestinal Stromal Tumor
Enrollment Status: Active, not recruiting
Publish Date: November 17, 2022
Intervention Type: Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active, not recruiting
Publish Date: November 16, 2022
Intervention Type: Drug, Other
Study Drugs: FluorouracilIrinotecan HydrochlorideLeucovorin CalciumVeliparib
Study Phase: Phase 2
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Enrollment Status: Active, not recruiting
Publish Date: November 14, 2022
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Biological, Other
Study Drugs: Anetumab RavtansinePembrolizumab
Study Phase: Phase 1/Phase 2
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: FluorouracilGemcitabine hydrochlorideIrinotecan hydrochlorideOxaliplatinPaclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas
Enrollment Status: Active, not recruiting
Publish Date: July 06, 2022
Intervention Type: Other, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Active, not recruiting
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drugs: PamrevlumabGemcitabineNab-paclitaxelFOLFIRINOX
Study Phase: Phase 3
A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)
Enrollment Status: Active, not recruiting
Publish Date: June 30, 2022
Intervention Type: Drug, Procedure
Study Drugs: CisplatinGemcitabineGemcitabine HydrochlorideVeliparib
Study Phase: Phase 2
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Enrollment Status: Active, not recruiting
Publish Date: June 21, 2022
Intervention Type: Biological
Study Drugs: MGD013MGD013+Margetuximab
Study Phase: Phase 1
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Active, not recruiting
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOXFOLFOX
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Active, not recruiting
Publish Date: May 19, 2022
Intervention Type: Drug
Study Drugs: SEA-CD40PembrolizumabGemcitabineNab-Paclitaxel
Study Phase: Phase 1
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma
Enrollment Status: Active, not recruiting
Publish Date: April 25, 2022
Intervention Type: Other, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: May 08, 2020
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1a/1b Study of CXCR4 Peptide Antagonist (LY2510924) Administered in Combination With the Anti-PD-L1 Antibody, Durvalumab (MEDI4736), in Advanced Refractory Solid Tumors
Enrollment Status: Terminated
Publish Date: August 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Biological
Study Phase: Phase 2
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
Enrollment Status: Terminated
Publish Date: March 19, 2019
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations
Enrollment Status: Completed
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: August 08, 2017
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Enrollment Status: Terminated
Publish Date: October 24, 2016
Intervention Type: Other, Drug
Study Phase: Phase 2
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Enrollment Status: Completed
Publish Date: August 14, 2015
Intervention Type: Drug, Other
Study Phase: Phase 1/Phase 2
Phase II Study of AZD2171 (NSC#732208) in Patients With Malignant Mesothelioma
Enrollment Status: Completed
Publish Date: July 31, 2014
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Dasatinib (NSC 732517) in Previously-Treated Patients With Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: May 19, 2014
Intervention Type: Drug, Other
Study Phase: Phase 2
A Randomized Phase II Study of Bevacizumab (NSC# 704865) and Gemcitabine in Combination With Either Cetuximab (NSC# 714692) or OSI-774 (NSC# 718781) in Patients With Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 15, 2014
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase II Trial Of The Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Hepatobiliary Cancer
Enrollment Status: Terminated
Publish Date: May 14, 2014
Intervention Type: Drug, Other
Study Phase: Phase 2
A Randomized Pilot Phase II Study of Immunization With Modified CEA (CAP1-6D) Peptide In Patients With Locally Advanced Or Surgically Resected Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: April 16, 2014
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Double Blind, Placebo Controlled Randomized Phase II Trial Of Gemcitabine And Cisplatin With Or Without The VEGF Inhibitor Bevacizumab (NSC #704865) In Patients With Malignant Mesotheloma
Enrollment Status: Completed
Publish Date: February 11, 2014
Intervention Type: Drug, Other, Biological
Study Phase: Phase 2
A Phase II Study of BAY 43-9006/Gemcitabine for Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: July 02, 2013
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 05, 2013
Intervention Type: Drug, Other, Biological
Study Phase: Phase 3
A Phase II Trial Of Bevacizumab (NSC#704865) Plus Gemcitabine In Patients With Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: January 24, 2013
Intervention Type: Drug, Other, Biological
Study Phase: Phase 2
A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma
Enrollment Status: Unknown status
Publish Date: May 28, 2008
Intervention Type: Drug
Study Phase: Phase 2
View 31 Less Clinical Trials -
183 Total Publications
ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels.
Journal: Annals of surgical oncology
Published: August 05, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
RM
Dr. Robert D. Marsh
Oncology | Hematology Oncology
Elite
Highly rated in
19
conditions
Oncology
Hematology Oncology

NorthShore University Health System

Arbor Counseling Center

1401 Mchenry Rd, 
Buffalo Grove, IL 
 33.0 mi

Robert Marsh is an Oncologist and a Hematologist Oncology expert in Buffalo Grove, Illinois. Marsh has been practicing medicine for over 45 years and is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, Familial Pancreatic Cancer, and Endoscopy. He is licensed to treat patients in Illinois. Marsh is currently accepting new patients.

MM
Dr. Mary F. Mulcahy
Oncology
Elite
Highly rated in
63
conditions
Oncology

Northwestern Medicine

Robert H Lurie Cancer Center

675 N Saint Clair St, 
Chicago, IL 
 7.3 mi

Mary Mulcahy is an Oncologist in Chicago, Illinois. Mulcahy has been practicing medicine for over 30 years and is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Cancer. She is also highly rated in 63 other conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Liver Cancer, Pancreatic Cancer, Familial Colorectal Cancer, and Liver Embolization. She is licensed to treat patients in Illinois. Mulcahy is currently accepting new patients.

WL
Dr. William T. Leslie
Hematology Oncology | Hematology | Oncology
Distinguished
Highly rated in
27
conditions
Hematology Oncology
Hematology
Oncology

Rush University System for Health

Division Of Hematology Oncology And Cell Therapy

1725 W Harrison St, 
Chicago, IL 
 6.6 mi

William Leslie is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Leslie has been practicing medicine for over 45 years and is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 27 other conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Pancreatic Cancer. He is licensed to treat patients in Illinois. Leslie is currently accepting new patients.